Hemofili A Tanılı Koroner Arter Bypass Operasyonu Geçiren Hastada Anestezi Yönetimi

Authors

Güneş Comba Cebeci
Deniz Karakaya

Synopsis

This case report discusses the perioperative anesthesia and coagulation management of a 78-year-old male patient weighing 60 kg diagnosed with Hemophilia A undergoing coronary artery bypass graft (CABG) surgery. Referred after experiencing an acute posterior myocardial infarction, the patient's thyroid function tests, cardiac evaluations, and coagulation parameters were assessed; his Factor VIII level was found to be 31.3% and the Factor VIII inhibitor test was negative. One hour prior to the operation, 3000 units of Factor VIII were administered, raising the factor level to 105% before proceeding to surgery. Intraoperatively, standard monitoring, general anesthesia induction, maintenance, and tranexamic acid infusion were performed. Heparinization was maintained during cardiopulmonary bypass (CPB), followed by heparin neutralization with protamin after CPB. Postoperatively, the FVIII level was measured at 47%, and 1500 U/day FVIII replacement was continued for 10 days. The patient, whose total chest tube drainage reached 2050 ml and who required no blood product transfusions or experienced major bleeding, was safely discharged after 10 days. It is demonstrated that intermittent FVIII replacement via a multidisciplinary approach allows major cardiac surgery to be performed safely.

References

Odonkor P, Srinivas A, Strauss E, et al. Perioperative Coagulation Management of a Hemophilia A Patient During Cardiac Surgery. Semin Cardiothorac Vasc Anesth. 2017 Dec;21(4):312-320..

Şahin F, Engin Ç, Yağdı T, et al. Hemofili A Tanılı hastada koroner arter By-pass operasyonunda aralıklı faktör VIII uygulaması ile başarılı kanama kontrolü. Ege Tıp Dergisi. 2011;50(2):133-5.

Kulkarni R, Soucie JM, Evatt BL. Prevalence and risk factors for heart disease among males with hemophilia. American Journal of Hematology. 2005;79(1):36-42.

Sramek A, Reiber J, Gerrits W, et al. Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation. 2001;104(7):762-7.

Kanellopoulou T, Nomikou E. Replacement therapy for coronary artery bypass surgery in patients with hemophilia A and B. Journal of Cardiac Surgery. 2018;33(2):76-82.

Shalabi A, Kachel E, Kogan A, et al.Cardiac surgery in patients with Hemophilia: is it safe? Journal of Cardiothoracic Surgery. 2020;15:1-6.

Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. Journal of Thrombosis and Haemostasis. 2012;10(8):1478-85.

Published

January 13, 2022

License

License